{"protocolSection":{"identificationModule":{"nctId":"NCT05624190","orgStudyIdInfo":{"id":"HX-A-2022041"},"organization":{"fullName":"Beijing Tiantan Hospital","class":"OTHER"},"briefTitle":"Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization","officialTitle":"Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator rhTNK-tPA) Thrombolysis for Acute Large Vessel Occlusion After Successful Mechanical Thrombectomy Recanalization -- A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial (ANGEL-TNK)","acronym":"ANGEL-TNK"},"statusModule":{"statusVerifiedDate":"2022-11","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-12","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2023-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-11-14","studyFirstSubmitQcDate":"2022-11-21","studyFirstPostDateStruct":{"date":"2022-11-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-11-24","lastUpdatePostDateStruct":{"date":"2022-11-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Zhongrong Miao","investigatorTitle":"Director of Department of interventional neurology","investigatorAffiliation":"Beijing Tiantan Hospital"},"leadSponsor":{"name":"Beijing Tiantan Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The goal of this clinical trial is to evaluate whether intra-arterial (IA) rhTNK-tPA thrombolysis can improve neurological outcomes in acute large vessel occlusion patients after successful mechanical thrombectomy (MT) recanalization between 4.5- 24 hours from symptom onset. Participants enrolled will be randomly assigned to study or control arm with a 1:1ratio. Study group will receive IA rhTNK-tPA thrombolysis (0.125 mg/kg, Max 12.5mg) plus best medical management, and control receive best medical management alone."},"conditionsModule":{"conditions":["Ischemic Stroke, Acute"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":256,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"TNK group","type":"EXPERIMENTAL","description":"Patients of this group will receive IA rhTNK-tPA plus Best Medical Management (BMM) after successful mechanical thrombectomy (MT) recanalization","interventionNames":["Drug: Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)","Other: Best Medical Management"]},{"label":"control group","type":"ACTIVE_COMPARATOR","description":"Patients of this group will receive Best Medical Management (BMM) alone after successful mechanical thrombectomy (MT) recanalization","interventionNames":["Other: Best Medical Management"]}],"interventions":[{"type":"DRUG","name":"Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)","description":"The administration of rhTNK-tPA will be infused constant and slowly over 15min (0.125 mg/kg, Max 12.5mg) through a microcatheter.","armGroupLabels":["TNK group"],"otherNames":["IA rhTNK-tPA"]},{"type":"OTHER","name":"Best Medical Management","description":"Best Medical Management","armGroupLabels":["TNK group","control group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Rate of excellent outcome","description":"Rate of 90 (±7) day modified Rankin scale (mRS) 0-1","timeFrame":"90±7 days after randomization"}],"secondaryOutcomes":[{"measure":"Rate of sICH (Heidelberg Bleeding Classification)","description":"Rate of sICH (Heidelberg Bleeding Classification)","timeFrame":"within 48 hours after randomization"},{"measure":"Volume of Tmax>6s","timeFrame":"24 hours (±12 hours) after randomization"},{"measure":"Infarct core volume change from baseline","description":"Infarct core volume change from baseline, assessed with NCCT at 7 days (±1 day) after randomization/at discharge or with MRI at 36 hours (±12 hours)","timeFrame":"7 days (±1 day) after randomization/at discharge or at 36 hours (±12 hours) after randomization"},{"measure":"mRS (shift analysis)","description":"mRS (shift analysis)","timeFrame":"90 days (±7 days) after randomization"},{"measure":"Rate of good outcome","description":"Rate of mRS 0-2","timeFrame":"90 days (±7 days) after randomization"},{"measure":"Rate of mRS 0-3","description":"Rate of mRS 0-3","timeFrame":"90 days (±7 days) after randomization"},{"measure":"NIHSS 0-1 or decrease ≥10 from baseline NIHSS","description":"NIHSS 0-1 or decrease ≥10 from baseline NIHSS","timeFrame":"36 hours (±12hours) after randomization"},{"measure":"EQ-5D-5L score","description":"EQ-5D-5L score","timeFrame":"90 days (±7 days) after randomization"},{"measure":"All-caused mortality","description":"All-caused mortality","timeFrame":"90 days (±7 days) after randomization"},{"measure":"Rate of any intracranial hemorrhage (Heidelberg Bleeding Classification)","description":"Rate of any intracranial hemorrhage (Heidelberg Bleeding Classification)","timeFrame":"within 48 hours after randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nClinical Inclusion Criteria:\n\n1. Age \\>18 years;\n2. NIHSS ≥2;\n3. Onset of symptoms to baseline CT imaging time: 4.5 to 24 hours, including wake-up stroke and unwitnessed stroke; Time of onset of symptoms is defined as \"last known well\" (LKW);\n4. Pre-stroke mRS score 0-1;\n5. Signed informed consent from patient or their health care proxy.\n\nNeuroimaging Inclusion Criteria:\n\n1. CTA/MRA proven intracranial artery occlusion: Intracranial Internal Carotid Artery (ICA)、M1 of Middle cerebral artery (MCA)、dominant M2 of MCA;\n2. ASPECTS ≥6 on non-contrast CT (NCCT) scan or DWI MRI;\n3. CT perfusion or MR perfusion: ischemic infarct core \\<70ml, mismatch ratio≥1.2, mismatch volume ≥15ml;\n4. Treated with MT resulting in an eTICI score 2b50-3 at end of the procedure. Patients with an eTICI score 2b50-3 on the diagnostic cerebral angiography before the onset of MT are also eligible for the study.\n\nExclusion Criteria:\n\nClinical Exclusion Criteria:\n\n1. IV thrombolysis used on admission;\n2. Contraindications to intravenous thrombolysis;\n3. Balloon angioplasty, permanent stenting and other situations during the endovascular procedure that require antiplatelet therapy or anticoagulant within the first 24h;\n4. IV heparin (heparinized saline allowed);\n5. Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test;\n6. Brain tumor (with mass effect);\n7. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency\n8. Known coagulopathy, INR\\>1.7 or use of novel anticoagulants \\< 48h from symptom onset\n9. Platelets \\< 50\\*109/L;\n10. Suspicion of septic emboli or endocarditis\n11. Renal Failure as defined by a serum creatinine \\> 2.5 mg/dl (or 220μmol/l) or glomerular Filtration Rate \\[GFR\\] \\< 30ml/min;\n12. Patient who requires hemodialysis or peritoneal dialysis, or who has a contraindication to angiogram for whatever reason;\n13. Suspicion of aortic dissection;\n14. Parenchymal organ surgery and biopsy were performed in the past one month;\n15. Any active bleeding or recent bleeding (gastrointestinal bleeding, urinary bleeding, etc.) in the past 1 month;\n16. History of life-threatening allergy (more than rash) to contrast medium;\n17. SBP \\>185 mmHg or DBP \\>110 mmHg refractory to treatment;\n18. Serious, advanced, terminal illness with anticipated life expectancy \\< 6 months;\n19. Participation in another randomized clinical trial that could confound the evaluation of the study;\n20. Other circumstances that the investigator considers inappropriate for participation or may pose a significant risk to patients (e.g. inability to understand and/or comply with study procedures and/or follow-up due to mental disorders, cognitive or mood disorders).\n\nSpecific Neuroimaging Exclusion Criteria\n\n1. Midline shift or herniation, mass effect with effacement of the ventricles\n2. Evidence of acute intracranial hemorrhage on CT/MRI\n3. Acute bilateral strokes or multiple intracranial vessel occlusions\n4. Isolated extracranial ICA occlusion or tandem carotid / MCA occlusion\n5. Dissection of occluded artery on DSA after thrombectomy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Xiaochuan Huo, Dr.","role":"CONTACT","phone":"+8613716292262","email":"huoxiaochuan@126.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke, Acute","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke, Acute","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010958","term":"Plasminogen"},{"id":"D000077785","term":"Tenecteplase"},{"id":"D000010959","term":"Tissue Plasminogen Activator"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Feed-back","relevance":"HIGH"},{"id":"M1911","name":"Tenecteplase","asFound":"Early Intervention","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","asFound":"Health-related Quality of Life","relevance":"HIGH"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}